6-methoxy-9-methyl-9H-β-carboline | 30684-43-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-methoxy-9-methyl-9H-β-carboline
• 英文别名: 7-methoxy-1-methyl-β-carboline；6-Methoxy-9-methyl-β-carbolin；9-Methyl-6-methoxynorharman；6-methoxy-9-methyl-9H-pyrido[3,4-b]indole；6-methoxy-9-methylpyrido[3,4-b]indole
• CAS: 30684-43-6
• 化学式: C₁₃H₁₂N₂O
• 分子量: 212.251
• InChiKey: XBRYDHQDILJNCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-methoxy-9-methyl-9H-β-carboline 在 氢溴酸 、 溶剂黄146 作用下， 生成 9-methyl-9H-β-carbolin-6-ol
  参考文献：
  名称：

  6-Hydroxy- and 6-methoxy-β-carbolines as acetyl- and butyrylcholinesterase inhibitors

  摘要：

  In the course of studies directed toward the discovery of novel acetyl- and butyrylcholinesterase (AChE and BChE) inhibitors for the treatment of Alzheimer's disease, we focused on beta-carbolines (BCs). 6-Oxygenated P-carboline and P-carbolinium derivatives based on the serotonin template were synthesized and tested in vitro for their ability to inhibit AChE and BChE, respectively. Particularly the carbolinium salts, which can be formed by intracerebral methylation out of the tertiary-BC prodrugs, show inhibitory activity levels reaching those of galantamine, physostigmine, and rivastigmine. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.067
• 作为产物：
  描述：

  5-甲氧基色胺盐酸盐 在 palladium on activated charcoal 盐酸 、 氢氧化钾 、 异丙苯 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 6-methoxy-9-methyl-9H-β-carboline
  参考文献：
  名称：

  6-Hydroxy- and 6-methoxy-β-carbolines as acetyl- and butyrylcholinesterase inhibitors

  摘要：

  In the course of studies directed toward the discovery of novel acetyl- and butyrylcholinesterase (AChE and BChE) inhibitors for the treatment of Alzheimer's disease, we focused on beta-carbolines (BCs). 6-Oxygenated P-carboline and P-carbolinium derivatives based on the serotonin template were synthesized and tested in vitro for their ability to inhibit AChE and BChE, respectively. Particularly the carbolinium salts, which can be formed by intracerebral methylation out of the tertiary-BC prodrugs, show inhibitory activity levels reaching those of galantamine, physostigmine, and rivastigmine. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.067

文献信息

• Substituted beta-carbolines
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1209158A1

  公开（公告）日：2002-05-29

  Compounds of the formula I are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of IκB kinase is involved.

  式I的化合物适用于生产用于预防和治疗在其过程中涉及IκB激酶活性增加的疾病的药物。
• BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO
  申请人：Rommelspacher Hans

  公开号：US20130028958A1

  公开（公告）日：2013-01-31

  The present invention is directed at β-carbolines, preferred 9-alkyl-β-carbolines ( 9 -alkyl-β-BC), their manufacture as well as their use in prophylaxis and treatment of hearing damages, tinnitus, acute acoustic trauma, vertigo and vestibular disorder as well as pharmaceutical compositions containing theses β-carbolines.

  本发明涉及β-咔唑啉，特别是9-烷基-β-咔唑啉（9-烷基-β-BC），其制造方法以及它们在预防和治疗听力损伤、耳鸣、急性声创伤、眩晕和前庭障碍方面的应用，以及包含这些β-咔唑啉的制药组合物。
• BETA-CARBOLINE ZUR BEHANDLUNG VON HÖRSCHÄDEN UND SCHWINDEL
  申请人：Audiocure Pharma GmbH

  公开号：EP2519238B1

  公开（公告）日：2014-08-13
• US7348336B2
  申请人：——

  公开号：US7348336B2

  公开（公告）日：2008-03-25
• US9107914B2
  申请人：——

  公开号：US9107914B2

  公开（公告）日：2015-08-18